PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34734507-9 2021 Alpha-galactosylceramide supplementation significantly increased the frequencies of drug-induced IFN-gamma releasing cells. alpha-galactosylceramide 0-24 interferon gamma Homo sapiens 97-106 31160756-3 2020 The persistent polarization of IL4 induced by strong lipid antigens, that is, alpha-galactosylceramide (alphaGC), caused IL4 accumulation at the immunological synapse (IS), which promoted the activation of the IL4R-STAT6 (signal transducer and activator of transcription 6) pathway and production of IL12 in DCs, which enhanced interferon-gamma (IFNgamma) production in iNKT cells. alpha-galactosylceramide 78-102 interferon gamma Homo sapiens 328-344 31160756-3 2020 The persistent polarization of IL4 induced by strong lipid antigens, that is, alpha-galactosylceramide (alphaGC), caused IL4 accumulation at the immunological synapse (IS), which promoted the activation of the IL4R-STAT6 (signal transducer and activator of transcription 6) pathway and production of IL12 in DCs, which enhanced interferon-gamma (IFNgamma) production in iNKT cells. alpha-galactosylceramide 78-102 interferon gamma Homo sapiens 346-354 32450553-5 2020 Proliferation and IFN-gamma production of circulating NKT cells in response to alpha-GalCer were markedly decreased in trauma patients. alpha-galactosylceramide 79-91 interferon gamma Homo sapiens 18-27 26862702-5 2016 The re-differentiated iNKT cells showed proliferation and IFN-gamma production in response to alpha-galactosylceramide, induced dendritic cell maturation and downstream activation of both cytotoxic T lymphocytes and NK cells, and exhibited NKG2D- and DNAM-1-mediated NK cell-like cytotoxicity against cancer cell lines. alpha-galactosylceramide 94-118 interferon gamma Homo sapiens 58-67 29975662-6 2018 The synthetic molecule alpha-galactosylceramide has also been shown to stimulate natural killer cell activation and interferon (IFN)-gamma secretion. alpha-galactosylceramide 23-47 interferon gamma Homo sapiens 116-138 28193627-9 2017 IFNgamma responses to alpha-galactosylceramide were increased in PBMCs from some patients after infusions, and delayed-type hypersensitivity responses to Candida increased in 5 of 8 evaluated patients. alpha-galactosylceramide 22-46 interferon gamma Homo sapiens 0-8 26215444-5 2015 An enzyme-linked immunosorbent assay (ELISA) was used to measure IL-4 and IFN-gamma secretion upon alpha-galactosylceramide (alpha-GalCer) activation ex vivo. alpha-galactosylceramide 99-123 interferon gamma Homo sapiens 74-83 26852856-1 2016 Alpha-galactosylceramide (GC) represents a potentially new class of adjuvant because GC strongly induces interferon (IFN) gamma production from natural killer T (NKT) cells, leading to the induction of strong antitumor immunity. alpha-galactosylceramide 0-24 interferon gamma Homo sapiens 105-127 26852856-1 2016 Alpha-galactosylceramide (GC) represents a potentially new class of adjuvant because GC strongly induces interferon (IFN) gamma production from natural killer T (NKT) cells, leading to the induction of strong antitumor immunity. alpha-galactosylceramide 26-28 interferon gamma Homo sapiens 105-127 22386518-4 2012 Vaccination with VLP and alpha-galactosylceramide activated splenic iNKT cells to produce IFN-gamma and IL-4, led to the generation of antigen-specific T cells that protected prophylactically against subcutaneous tumor challenge, and was more effective at generating anti-tumor immune responses than either component individually. alpha-galactosylceramide 25-49 interferon gamma Homo sapiens 90-99 26121617-5 2015 When primary T cells transfected with NKT cell-derived TCR were subsequently stimulated with the NKT ligand, alpha-galactosylceramide (alpha-GalCer), they secreted IFN-gamma in a ligand-specific manner. alpha-galactosylceramide 109-133 interferon gamma Homo sapiens 164-173 25499027-9 2015 Chronic alcohol consumption increases the percentage of IFN-gamma-producing iNKT cells and increases the blood concentration of IFN-gamma and IL-12 after in vivo alpha-galactosylceramide (alphaGalCer) stimulation. alpha-galactosylceramide 162-186 interferon gamma Homo sapiens 128-137 22534863-1 2012 PURPOSE: The intravenous administration of alpha-Galactosylceramide (alpha-GalCer)-pulsed antigen presenting cells (APCs) is well tolerated and the increased IFN-gamma producing cells in the peripheral blood after the treatment appeared to be associated with prolonged survival. alpha-galactosylceramide 43-67 interferon gamma Homo sapiens 158-167 23028326-4 2012 Despite this difference, mangabey NKT lymphocytes were functionally distinct from both macaque species in their ability to secrete significantly more IFN-gamma, IL-13, and IL-17 in response to CD1d/alpha-galactosylceramide stimulation. alpha-galactosylceramide 198-222 interferon gamma Homo sapiens 150-159 22581860-4 2012 Keratinocytes loaded with alpha-galactosyl ceramide (alpha-GalCer) could stimulate IFN-gamma production and CD25 upregulation by iNKT cells. alpha-galactosylceramide 26-51 interferon gamma Homo sapiens 83-92 22581860-4 2012 Keratinocytes loaded with alpha-galactosyl ceramide (alpha-GalCer) could stimulate IFN-gamma production and CD25 upregulation by iNKT cells. alpha-galactosylceramide 53-65 interferon gamma Homo sapiens 83-92 20942806-10 2010 alpha-Galactosylceramide (alphaGalCer) stimulation of peripheral blood mononuclear cells or isolated NK T cell lines from both patients induced IFN-gamma, but no IL-4 and no response towards autologous tumour cells or lysates. alpha-galactosylceramide 0-24 interferon gamma Homo sapiens 144-153 22195564-2 2011 The first antigen described, alpha-galactosyl ceramide (alphaGalCer), is a potential anticancer agent whose activity depends upon IFN-gamma secretion. alpha-galactosylceramide 29-54 interferon gamma Homo sapiens 130-139 21245578-1 2011 Type 1 or invariant NKT (iNKT) cell agonists, epitomized by alpha-galactosylceramide, protect against cancer largely by IFN-gamma-dependent mechanisms. alpha-galactosylceramide 60-84 interferon gamma Homo sapiens 120-129 21283989-2 2011 Very few compounds have been found to stimulate iNKT cells, and of these, the best characterised is the glycolipid alpha-galactosylceramide, which stimulates the production of large quantities of interferon-gamma (IFN-gamma) and interleukin-4 (IL-4). alpha-galactosylceramide 115-139 interferon gamma Homo sapiens 196-212 21283989-2 2011 Very few compounds have been found to stimulate iNKT cells, and of these, the best characterised is the glycolipid alpha-galactosylceramide, which stimulates the production of large quantities of interferon-gamma (IFN-gamma) and interleukin-4 (IL-4). alpha-galactosylceramide 115-139 interferon gamma Homo sapiens 214-223 20804502-0 2010 A set of genes associated with the interferon-gamma response of lung cancer patients undergoing alpha-galactosylceramide-pulsed dendritic cell therapy. alpha-galactosylceramide 96-120 interferon gamma Homo sapiens 35-51 17266209-3 2007 We found that this isosteric replacement of alpha-GalCer"s amide moiety with triazole increases the IL-4 versus IFN-gamma bias of released cytokines. alpha-galactosylceramide 44-56 interferon gamma Homo sapiens 112-121 20508728-5 2010 alpha-galactosylceramide (alpha-GalCer)-activated type I NKT cells secrete both Th1 (e.g., IFN-gamma) and Th2 cytokines, affect the expression of costimulatory molecules in immune cells, and regulate the host immune system. alpha-galactosylceramide 0-24 interferon gamma Homo sapiens 91-100 17277112-3 2007 Hepatic (alpha-galactosyl-ceramide-loaded CD1d dimer binding) NKT cells produce predominantly IL-4 when stimulated with glycolipid-presenting HC but predominantly IFN-gamma when stimulated with glycolipid-presenting dendritic cells. alpha-galactosylceramide 9-34 interferon gamma Homo sapiens 163-172 20410589-4 2010 Al-though alpha-galactosylceramide (alpha-GalCer) presented by CD11c-positive cells induced both interferon-gamma (IFN-gamma) and IL-4 release, all of AGLs presented by CD11c-positive cells and AGL-1 presented by B cells induced IL-4 release from iNKT hybridoma cells. alpha-galactosylceramide 10-34 interferon gamma Homo sapiens 97-113 20410589-4 2010 Al-though alpha-galactosylceramide (alpha-GalCer) presented by CD11c-positive cells induced both interferon-gamma (IFN-gamma) and IL-4 release, all of AGLs presented by CD11c-positive cells and AGL-1 presented by B cells induced IL-4 release from iNKT hybridoma cells. alpha-galactosylceramide 10-34 interferon gamma Homo sapiens 115-124 18706662-6 2008 A striking functional finding was that while NKT-cells in unfractionated peripheral blood from healthy subjects expanded in number and produced IFN-gamma upon stimulation with alpha-galactosylceramide, NKT-cells from MS patients did not. alpha-galactosylceramide 176-200 interferon gamma Homo sapiens 144-153 18350544-4 2008 The CD4 subset stimulated by alpha-galactosylceramide (alpha-GalCer)-loaded DC immediately produced massive amounts of IL-4 and IL-13, which together with IFN-gamma enhanced CD40L-induced IL-12 production by DC. alpha-galactosylceramide 29-53 interferon gamma Homo sapiens 155-164 18350544-4 2008 The CD4 subset stimulated by alpha-galactosylceramide (alpha-GalCer)-loaded DC immediately produced massive amounts of IL-4 and IL-13, which together with IFN-gamma enhanced CD40L-induced IL-12 production by DC. alpha-galactosylceramide 55-67 interferon gamma Homo sapiens 155-164 18178816-5 2008 We show that PGD2 dramatically reduced the production of IFN-gamma, but not IL-4, by iNKT cells in response to the superagonist alpha-galactosylceramide (alpha-GalCer) both in vitro and in vivo. alpha-galactosylceramide 128-152 interferon gamma Homo sapiens 57-66 16186183-5 2005 Early graft loss was successfully prevented through the repeated administration of alpha-galactosylceramide, a specific ligand for Valpha14 NKT cells, resulting in dramatically reduced IFN-gamma production by Gr-1+CD11b+ cells, as well as Valpha14 NKT cells. alpha-galactosylceramide 83-107 interferon gamma Homo sapiens 185-194 17015708-5 2006 Surprisingly, the cytokine production of iNKT cells stimulated by alpha-galactosylceramide presented by CD1d+ Schwann cells showed a predominance of Th2-associated cytokines such as IL-5 and IL-13 with a marked deficiency of proinflammatory Th1 cytokines such as IFN-gamma or TNF-alpha. alpha-galactosylceramide 66-90 interferon gamma Homo sapiens 263-272 16505600-3 2006 iNKT cells recognize glycolipid antigens such as alpha-galactosylceramide (alpha-GC) presented by CD1d, non-pormorphic MHC class I-like molecule, and rapidly secrete large amounts of cytokines including IL-4 and IFN-gamma upon activation. alpha-galactosylceramide 49-73 interferon gamma Homo sapiens 212-221 16505600-3 2006 iNKT cells recognize glycolipid antigens such as alpha-galactosylceramide (alpha-GC) presented by CD1d, non-pormorphic MHC class I-like molecule, and rapidly secrete large amounts of cytokines including IL-4 and IFN-gamma upon activation. alpha-galactosylceramide 75-83 interferon gamma Homo sapiens 212-221 15922476-1 2005 BACKGROUND/AIMS: The functions of mouse liver NK1.1+ T (NKT) cells stimulated with alpha-galactosylceramide (alpha-GalCer) are enhanced age dependently, and the antitumor and anti-metastatic effect in the liver is dependent on IFN-gamma. alpha-galactosylceramide 83-107 interferon gamma Homo sapiens 227-236 15922476-1 2005 BACKGROUND/AIMS: The functions of mouse liver NK1.1+ T (NKT) cells stimulated with alpha-galactosylceramide (alpha-GalCer) are enhanced age dependently, and the antitumor and anti-metastatic effect in the liver is dependent on IFN-gamma. alpha-galactosylceramide 109-121 interferon gamma Homo sapiens 227-236 15778340-2 2005 In this report, we first demonstrate that the downstream effects induced by alpha-galactosylceramide activated NK T cells on NK cells are mainly dependent on IFN-gamma. alpha-galactosylceramide 76-100 interferon gamma Homo sapiens 158-167 15574787-4 2004 In contrast with the NKT cell agonist alpha-galactosylceramide, which induces both IFN-gamma and IL-4 production by NKT cells, CpG-liposome only induced IFN-gamma production by NKT cells. alpha-galactosylceramide 38-62 interferon gamma Homo sapiens 83-92 12902477-7 2003 Importantly, human hepatic Valpha24(+) T cells are potent producers of IFN-gamma and TNF-alpha, but not IL-2 or IL-4, when stimulated pharmacologically or with the NKT cell ligand, alpha-galactosylceramide. alpha-galactosylceramide 181-205 interferon gamma Homo sapiens 71-80 14734606-5 2004 When stimulated with the specific glycolipid ligand, alpha-galactosylceramide, peripheral blood V(alpha)24 NKT cells from patients with non-remitting disease produced significantly less IFN-gamma than those from healthy volunteers, but normal levels of IL-4. alpha-galactosylceramide 53-77 interferon gamma Homo sapiens 186-195 14734609-2 2004 Stimulation via their invariant Valpha14 receptor with anti-CD3 or a ligand, alpha-galactosylceramide (alpha-GalCer), triggers activation of Valpha14 NKT cells, resulting in a rapid cytokine production such as IFN-gamma and IL-4. alpha-galactosylceramide 77-101 interferon gamma Homo sapiens 210-219 15259008-7 2004 NKT cells expressing the Valpha24Vbeta11 TCR, which recognizes CD1d,were virtually absent from the intestine, but colonic cells produced IFN-gamma in response to the NKT cell agonist ligand alpha-galactosylceramide. alpha-galactosylceramide 190-214 interferon gamma Homo sapiens 137-146 12902477-9 2003 However, hepatic cells from cancer patients and healthy donors release similar amounts of IFN-gamma in response to alpha-galactosylceramide. alpha-galactosylceramide 115-139 interferon gamma Homo sapiens 90-99 12962036-2 2003 Although a prototype natural killer T(NKT) cell ligand, alpha-galactosylceramide(alpha-GC), would render NKT cells produce both IFN-gamma and IL-4, this novel ligand, an analog of alpha-GC with a truncated sphingosine chain, can induce a predominant production of IL-4. alpha-galactosylceramide 56-80 interferon gamma Homo sapiens 128-137 12444115-1 2002 We recently reported that the direct antitumor effectors in the liver induced by alpha-galactosylceramide (alpha-GalCer) are NK cells that are activated by the IFN-gamma produced from NK1.1 Ag(+) T cells (NKT cells) specifically stimulated with alpha-GalCer, whereas NKT cells cause hepatocyte injury through the Fas-Fas ligand pathway. alpha-galactosylceramide 81-105 interferon gamma Homo sapiens 160-169 11830474-0 2002 Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. alpha-galactosylceramide 133-157 interferon gamma Homo sapiens 25-41 11164462-9 2000 Another subset of T cells that expresses the NK receptors is the alpha-galactosyl-ceramide specific T cell subset defined by the expression of canonical Valpha24JalphaQ TCR, recognition of CD1d and secretion of high amounts of IL-4 and IFN-gamma. alpha-galactosylceramide 65-90 interferon gamma Homo sapiens 236-245